8-K: Akebia Therapeutics Reports Vafseo Launch Progress and Year-End Financials

Akebia Therapeutics announces strong initial results from the Vafseo U.S. launch and anticipates Q1 2025 net product revenues of $10-$11 million.

Summary

• Akebia Therapeutics reported its fourth quarter and full-year 2024 financial results, highlighting the commercial launch of Vafseo (vadadustat).
• Vafseo shipments began on January 9, 2025, and the company expects $10-$11 million in net product revenues for the first quarter of 2025.
• The company has secured commercial supply contracts with dialysis organizations covering nearly 100% of U.S. dialysis patients.
• Akebia plans to meet with the FDA to discuss the Phase 3 VALOR study protocol for expanding Vafseo's label to non-dialysis CKD patients, with the study expected to begin in the second half of 2025.
• Total revenues for Q4 2024 were $46.5 million, compared to $56.2 million in Q4 2023, and full-year revenues were $160.2 million, down from $194.6 million in the previous year.
• Auryxia net product revenues were $44.4 million for Q4 2024 and $152.2 million for the full year, reflecting a decrease primarily due to lower volume.
• The net loss for Q4 2024 was $22.8 million, compared to a net income of $0.6 million in Q4 2023, and the full-year net loss was $69.4 million, compared to $51.9 million in the previous year.
• Akebia's cash and cash equivalents as of December 31, 2024, were approximately $51.9 million, with expectations to fund the current operating plan for at least two years.
• Post year-end, the company raised $18.4 million through share sales and accessed $9.3 million from Tranche C of the BlackRock Credit Agreement.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is launching a new product and expects revenue growth, but faces challenges with declining revenues from existing products and increasing net losses.

Positives

• Vafseo's U.S. launch is underway with strong initial results, including commercial supply contracts covering nearly 100% of U.S. dialysis patients.
• Akebia expects Vafseo net product revenue of approximately $10-$11 million in the first quarter of 2025.
• The company has sufficient cash resources and expects cash from operations to fund its current operating plan for at least two years.
• Vafseo has been recommended for symptomatic anemia in adults undergoing dialysis for CKD by the U.K. National Institute for Health and Care Excellence (NICE).
• U.S. Renal Care has enrolled more than half of the total target of 2,200 patients in VOICE, a collaborative clinical trial of Vafseo designed to assess mortality and hospitalization.

Negatives

• Total revenues decreased to $46.5 million in Q4 2024 from $56.2 million in Q4 2023.
• Auryxia net product revenues decreased to $44.4 million in Q4 2024 from $53.2 million in Q4 2023, primarily due to a reduction in volume.
• The net loss increased to $22.8 million in Q4 2024 from a net income of $0.6 million in Q4 2023.
• Full-year 2024 net loss was $69.4 million, compared to $51.9 million for the full-year 2023.

Risks

• The company faces risks associated with the commercial availability and market acceptance of Vafseo.
• There are competitive pressures from potential generic entrants for Auryxia and Vafseo.
• Decisions made by health authorities, such as the FDA, could impact regulatory filings and interactions.
• Manufacturing, supply chain, and quality issues could lead to recalls, write-downs, or impairments.
• Early termination of collaborations could negatively impact the company's financial position.

Future Outlook

Akebia expects Vafseo first quarter 2025 net product revenues of approximately $10-$11 million and anticipates its existing cash resources and cash from operations will be sufficient to fund its current operating plan for at least two years. The company also plans to initiate a Phase 3 clinical trial (VALOR) in the second half of 2025 to study the use of vadadustat in treating anemia in late-stage CKD patients who are not on dialysis.

Management Comments

• John P. Butler, Chief Executive Officer of Akebia, stated, 'We believe Vafseo can be a new standard of care for the treatment of anemia due to chronic kidney disease (CKD).'
• Mr. Butler continued, 'We are very pleased with the early results and expect to generate Vafseo net product revenue of approximately $10-$11 million in the first quarter of 2025.'

Industry Context

Akebia's focus on kidney disease and anemia treatment aligns with the growing prevalence of chronic kidney disease globally. The launch of Vafseo and its potential expansion to non-dialysis patients positions Akebia to compete with existing treatments like erythropoietin stimulating agents (ESAs). The recommendation of Vafseo by the U.K.'s NICE also highlights its potential for global adoption.

Comparison to Industry Standards

• Vafseo competes with existing ESAs like Amgen's Epogen and Aranesp, as well as other HIF-PH inhibitors like GSK's Duvroq.
• The TDAPA reimbursement secured by Akebia is a significant advantage compared to previous drug launches in the dialysis space.
• The VOICE trial is designed to assess mortality and hospitalization, similar to studies conducted for other anemia treatments in CKD patients.
• Akebia's financial performance is being compared to other biopharmaceutical companies focused on kidney disease, such as Ardelyx and Tricida.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the success of Vafseo's launch.
• Employees are affected by the company's cost avoidance measures and operating expense reductions.
• Patients with CKD may benefit from the availability of Vafseo as a new treatment option.
• Dialysis organizations are key customers for Vafseo, and their adoption of the drug will impact Akebia's revenue.
• Suppliers and creditors are affected by the company's financial stability and ability to meet its obligations.

Next Steps

• Akebia plans to meet with the FDA to discuss the Phase 3 VALOR study protocol.
• The company expects to initiate the VALOR clinical trial in the second half of 2025.
• Akebia will continue to monitor the commercial launch of Vafseo and its market penetration.

Key Dates